Company Profile

ANG LIFESCIENCES INDIA LTD.

NSE : NABSE : 540694ISIN CODE : INE236W01016Industry : Pharmaceuticals & DrugsHouse : Private
BSE561.00-21.6 (-3.71 % )
PREV CLOSE (Rs.) 582.60
OPEN PRICE (Rs.) 576.60
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 21224
TODAY'S LOW / HIGH (Rs.)553.60 579.90
52 WK LOW / HIGH (Rs.) 35.75 800.45
NSE
This Company is not listed in NSE

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.00
TTM EPS (Rs.) 6.78
P/E Ratio 82.45
Book Value (Rs.) 38.33
Face Value (Rs.) 10
MCap (Rs. in Mn) 5794.43
Price/Earning (TTM) 69.44
Price/Sales (TTM) 3.75
Price/Book (MRQ) 14.58
PAT Margin (%) 4.81
ROCE (%) 22.39
Incorporation Year : 2006

Management Info :

- Chairman Rajesh Gupta - Managing Director

Registered Office :

Address : Darbara Complex, Sco 113, First Floor,District Shopping Centre, B Block Ranjit Avenue,Amritsar,
Amritsar,
Punjab-143001

Phone : 0183 5133455, 5133473

Registrar's Details : Bigshare Services Pvt Ltd
Bharat Tin Works Building,1st floor, Opp. Vasant Oasis,Andheri (E),Mumbai
Listing : BSE
NEWS More
26Nov11-26-2021$ANG Lifesciences India trades in green on the BSE ANG Lifesciences India trade

ANG Lifesciences India is currently trading at Rs. 559.60, up by 11.90 points or 2.17% from its previous closing of Rs. 547.70 on the BSE.

The scrip opened at Rs. 547.70 and has touched a high and low of Rs. 575.05 and Rs. 520.35 respectively. So far 84760 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 800.45 on 09-Nov-2021 and a 52 week low of Rs. 35.75 on 01-Jan-2021.

Last one week high and low of the scrip stood at Rs. 575.05 and Rs. 472.05 respectively. The current market cap of the company is Rs. 590.90 crore.

The promoters holding in the company stood at 71.07% and Non-Institutions held 28.93%.

ANG Lifesciences India’s board has decided to invest in the equity shares of ANG Healthcare India. Therefore consequent to the acquisition of 100% Equity stake by the company, ANG Healthcare India will become Wholly-Owned Subsidiary Company of ANG Lifesciences India.

The acquisition will help company in its brand-building, domestic branding and direct marketing initiative for the purposes of staying close to the customer and to serve its vision of providing innovative and high quality products at affordable prices all across the country following ethical business practices. The company’s Board of Directors in their meeting held on November 23, 2021, has decided to the same.

ANG Lifesciences India, incorporated in the year 2006, started with the business of manufacturing and marketing of finished pharmaceutical formulation in a dosage form of Sterile Dry Powder Injection Vial.

ANG Lifesciences India is currently trading at Rs. 559.60, up b..
25Nov11-25-2021$ANG Lifesciences India touches roof on the BSE ANG Lifesciences India touch

ANG Lifesciences is locked its upper circuit limit at Rs. 547.70, up by 26.05 points or 4.99% from its previous closing of Rs. 521.65 on the BSE.

The scrip opened at Rs. 547.70 and has touched a high and low of Rs. 547.70 and Rs. 544.95 respectively. So far 14960 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 800.45 on 09-Nov-2021 and a 52 week low of Rs. 35.75 on 01-Jan-2021.

Last one week high and low of the scrip stood at Rs. 550.45 and Rs. 472.05 respectively. The current market cap of the company is Rs. 567.78 crore.

The promoters holding in the company stood at 71.07% and Non-Institutions held 28.93%.

ANG Lifesciences India’s board has decided to invest in the equity shares of ANG Healthcare India. Therefore consequent to the acquisition of 100% Equity stake by the company, ANG Healthcare India will become Wholly-Owned Subsidiary Company of ANG Lifesciences India.

The acquisition will help company in its brand-building, domestic branding and direct marketing initiative for the purposes of staying close to the customer and to serve its vision of providing innovative and high quality products at affordable prices all across the country following ethical business practices. The company’s Board of Directors in their meeting held on November 23, 2021, has decided to the same.

ANG Lifesciences India, incorporated in the year 2006, started with the business of manufacturing and marketing of finished pharmaceutical formulation in a dosage form of Sterile Dry Powder Injection Vial.

ANG Lifesciences is locked its upper circuit limit at Rs. 547.7..
24Nov11-24-2021$ANG Lifesciences gets nod to invest in ANG Healthcare India ANG Lifesciences gets nod to

ANG Lifesciences India’s board has decided to invest in the equity shares of ANG Healthcare India. Therefore consequent to the acquisition of 100% Equity stake by the company, ANG Healthcare India will become Wholly-Owned Subsidiary Company of ANG Lifesciences India. 

The acquisition will help company in its brand-building, domestic branding and direct marketing initiative for the purposes of staying close to the customer and to serve its vision of providing innovative and high quality products at affordable prices all across the country following ethical business practices. The company’s Board of Directors in their meeting held on November 23, 2021, has decided to the same. 

ANG Lifesciences India, incorporated in the year 2006, started with the business of manufacturing and marketing of finished pharmaceutical formulation in a dosage form of Sterile Dry Powder Injection Vial.

ANG Lifesciences India’s board has decided to invest in the e..
24Nov11-24-2021$ANG Lifesciences touches roof on getting nod to invest in ANG Healthcare India ANG Lifesciences touches roo

ANG Lifesciences is locked its upper circuit limit at Rs. 521.65, up by 24.80 points or 4.99% from its previous closing of Rs. 496.85 on the BSE.

The scrip opened at Rs. 472.05 and has touched a high and low of Rs. 521.65 and Rs. 472.05 respectively. So far 69765 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 800.45 on 09-Nov-2021 and a 52 week low of Rs. 35.75 on 01-Jan-2021.

Last one week high and low of the scrip stood at Rs. 550.45 and Rs. 472.05 respectively. The current market cap of the company is Rs. 540.78 crore.

The promoters holding in the company stood at 71.07 % while Non-Institutions held 28.93%.

ANG Lifesciences India’s board has decided to invest in the equity shares of ANG Healthcare India. Therefore consequent to the acquisition of 100% Equity stake by the company, ANG Healthcare India will become Wholly-Owned Subsidiary Company of ANG Lifesciences India.

The acquisition will help company in its brand-building, domestic branding and direct marketing initiative for the purposes of staying close to the customer and to serve its vision of providing innovative and high quality products at affordable prices all across the country following ethical business practices. The company’s Board of Directors in their meeting held on November 23, 2021, has decided to the same.

ANG Lifesciences India, incorporated in the year 2006, started with the business of manufacturing and marketing of finished pharmaceutical formulation in a dosage form of Sterile Dry Powder Injection Vial.

ANG Lifesciences is locked its upper circuit limit at Rs. 521.6..
09Nov11-09-2021$ANG Lifesciences India informs about company updates ANG Lifesciences India infor
ANG Lifesciences India has informed that the Company's Board of Directors in their meeting held on 08.11.2021, had decided to invest in the Equity Shares and Redeemable Cumulative Preference Shares of Baddi Agro. Consequent to the acquisition of 51% Equity stake by the Company, Baddi Agro will become the Subsidiary Company of ANG Lifesciences India. Baddi Agro has manufacturing unit situated at Baddi Himachal Pradesh (formerly known as Surya Pharmaceutical) which is laced with latest machinery and located proximate to Mentha Leaf cultivation area. The details required under regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 are given as an Annexure -A.

The above information is a part of company’s filings submitted to BSE.

ANG Lifesciences India has informed that the Company's Board of..
Financials More
Rs. in Millions
QTR ANNUAL 21
Net Profit70.28
Gross Profit 101.39
Operating Profit 144.22
Net Sales 1543.79
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
TTK Healthcare (BSE)
 770.00 (13.30%)
M.Cap ( in Cr)
1093.41
Pfizer (BSE)
 4896.00 (0.83%)
M.Cap ( in Cr)
22223.33
Ajanta Pharma (BSE)
 2132.05 (1.78%)
M.Cap ( in Cr)
17920.69
Natco Pharma (BSE)
 866.75 (3.88%)
M.Cap ( in Cr)
15768.58
Glaxosmithkline Phar (BSE)
 1876.00 (1.75%)
M.Cap ( in Cr)
31519.69
Shareholding Pattern More
PROMOTERS 71.07 %
NON-INSTITUTION 28.93 %
MUTUAL FUNDS/UTI 0 %
FI/BANKS/INSURANCE 0 %
GOVERNMENT 0 %
FII 0 %
MF HOLDINGS
Scheme NameHold(%)
No Data Found
F & O Quotes